Beam Therapeutics Inc.
BEAM Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$23.79
KIRA · Stoqly’s AI analyst, in plain words
- Beam Therapeutics Inc. had $140M of revenue in fiscal 2025, up 120.0% on the year before. Over five years, revenue changed +466.3% a year on average.
- Its operating margin was −274.6%, up 379.7 pts: of every 100 in sales, about −275 is left after running the business.
- Beam Therapeutics Inc. lost $80.0M in fiscal 2025.
- Free cash flow was −$360M in fiscal 2025, −257.7% of revenue.
Market cap
$2.5B
P/E
—
Revenue
$140M
Net income
−$80.0M
Free cash flow
−$360M
Operating margin
−274.6%
Beam Therapeutics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+120.0%
Yes. Sales grew 120.0% last year.
Does it make a profit?
−57.2%
No. It lost money last year.
Does profit turn into cash?
−257.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Beam Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Beam Therapeutics Inc.
- CIK
- 0001745999
Beam Therapeutics Inc. · BEAM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $51.8M | $60.9M | $378M | $63.5M | $140M |
| Revenue growth | 215,916.7% | 17.5% | 520.0% | −83.2% | 120.0% |
| Operating margin | −757.0% | −555.6% | −46.7% | −654.3% | −274.6% |
| Net income | −$371M | −$289M | −$133M | −$377M | −$80.0M |
| Net margin | −714.9% | −474.5% | −35.1% | −593.1% | −57.2% |
| Diluted EPS | −$5.77 | −$4.13 | −$1.72 | −$4.58 | −$0.81 |
| Cash | |||||
| Cash from operations | −$66.3M | $22.5M | −$149M | −$347M | −$345M |
| Capital expenditure | $46.8M | $49.0M | $33.7M | $8.9M | $14.9M |
| Free cash flow | −$113M | −$26.4M | −$183M | −$356M | −$360M |
| FCF margin | −218.1% | −43.4% | −48.4% | −560.8% | −257.7% |
| Share count change | 37.4% | 9.0% | 10.2% | 6.7% | 20.2% |
| Debt and strength | |||||
| Cash and short-term investments | $560M | $1.1B | $1.2B | $851M | $1.2B |
| Shareholders' equity | $827M | $733M | $981M | $734M | $1.2B |
| Current ratio | 6.0x | 4.9x | 5.9x | 4.8x | 13.1x |
| Returns and quality | |||||
| Return on equity | −69.1% | −37.1% | −15.5% | −43.9% | −8.1% |
| Return on tangible equity | −44.8% | −39.4% | −13.5% | −51.4% | −6.5% |
| Piotroski F-score | 4 | 4 | 3 | 1 | 3 |
| Altman Z'' | 2.6 | 1.3 | 3.2 | −0.9 | 5.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$19.7M
7 insiders
Of sales under plans
49%
$9.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Beam Therapeutics Inc. · BEAM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $23.79 a share, the company is worth $2.5B.
Source: SEC EDGAR XBRL filings (CIK 0001745999). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.